ParkinsonCanadaV1, Main, Exploration, bibRecord, 002A96

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease

Identifieur interne : 002A96 ( Main/Exploration ); précédent : 002A95; suivant : 002A97

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease

Auteurs : Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0262059

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Topiramate, Lévodopa, Dyskinésie, Modèle, Parkinson maladie.

English descriptors

KwdEn :
- Dyskinesia, Levodopa, Models, Nervous system diseases, Parkinson disease, Topiramate.

Abstract

Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000913
to stream PascalFrancis, to step Curation: 000410
to stream PascalFrancis, to step Checkpoint: 000760
to stream Main, to step Merge: 002E28
to stream Main, to step Curation: 002A96

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease</title>
<author><name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, Hope Hospital</s1>
<s2>Salford, Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Nicholson, S L" sort="Nicholson, S L" uniqKey="Nicholson S" first="S. L." last="Nicholson">S. L. Nicholson</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Motac Neuroscience Ltd., Williams House, Manchester Science Park</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Toronto Western Research Institute, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0262059</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0262059 INIST</idno>
<idno type="RBID">Pascal:05-0262059</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000913</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000410</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000760</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000760</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Silverdale M:topiramate:reduces:levodopa</idno>
<idno type="wicri:Area/Main/Merge">002E28</idno>
<idno type="wicri:Area/Main/Curation">002A96</idno>
<idno type="wicri:Area/Main/Exploration">002A96</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease</title>
<author><name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, Hope Hospital</s1>
<s2>Salford, Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Nicholson, S L" sort="Nicholson, S L" uniqKey="Nicholson S" first="S. L." last="Nicholson">S. L. Nicholson</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Motac Neuroscience Ltd., Williams House, Manchester Science Park</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Toronto Western Research Institute, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Levodopa</term>
<term>Models</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Topiramate</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Topiramate</term>
<term>Lévodopa</term>
<term>Dyskinésie</term>
<term>Modèle</term>
<term>Parkinson maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Manchester</li>
</region>
<settlement><li>Manchester</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
</region>
<name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<name sortKey="Nicholson, S L" sort="Nicholson, S L" uniqKey="Nicholson S" first="S. L." last="Nicholson">S. L. Nicholson</name>
<name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
</country>
<country name="Canada"><noRegion><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A96 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A96 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0262059
   |texte=   Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri